A phase II open label study of CB7630 (abiraterone acetate) in patients with advanced prostate cancer who have failed androgen deprivation and docetaxel-based chemotherapy.

Trial Profile

A phase II open label study of CB7630 (abiraterone acetate) in patients with advanced prostate cancer who have failed androgen deprivation and docetaxel-based chemotherapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Abiraterone acetate (Primary) ; Corticosteroids
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Cougar Biotechnology
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 08 Aug 2012 Actual end date (1 Aug 2011) added as reported by ClinicalTrials.gov.
    • 16 Feb 2011 Planned end date changed from 1 Dec 2007 to 1 Jun 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top